RxDoctor Payments Data

Jennifer Meyfeldt, MD

Internal Medicine · Phoenix, AZNPI 1326544701

Payments from drug & device makers

$3,641in general payments, 2019–2025

Across 105 payments — averaging $34.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$548
  • Lilly USA, LLC$516
  • Boehringer Ingelheim$315
  • Johnson & Johnson$250
  • Pulmonx Corporation$176
  • plus $750 from 19 others

What the payments were for

  • Food & beverage$3,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,641 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$28,121
Medicare patients
138
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$67,509
MounjaroTirzepatide33$35,565
OzempicSemaglutide28$26,764
TrulicityDulaglutide17$20,524
EliquisApixaban18$16,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,606
Tresiba Flextouch U-100Insulin Degludec12$5,500
Bupropion XlBupropion Hcl25$4,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,233
Pregabalin19$1,982
Rosuvastatin Calcium88$1,422
Gabapentin70$1,307
Duloxetine Hcl36$1,143
Levothyroxine Sodium130$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$315$67,50979 claims
Lilly USA, LLCMounjaro, Trulicity$516$56,08950 claims
Novo NordiskOzempic$65$26,76428 claims
PfizerEliquis$79$16,39918 claims
AstraZenecaBreztri Aerosphere$1,086$8,60613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →